中文     English
BFC Healthcare Conference

BFC Healthcare Conference

 BFC Healthcare Business Development and Investment Conference  BFC 2015 Global Healthcare Business Development and Investment Conference was held on May 13~14 at the Park Hotel in Shanghai. The conference featured presentations from over 65 public & private healthcare companies across the biopharmaceuticals, IVD, medi...

China Forum  V

China Forum V

China Forum  V   This is the fifth year that OneMedPlace in partnership with The Pharma Partners to organize China forum V on January 14 and January 15 at San Francisco Marriott Marquis, 55 Fourth Street, San Francisco, Ca.  We are expecting to have more than 100 companies from both US and China to participate the conference.  ...

BFC Spoke at  US-China Pharma Conference

BFC Spoke at US-China Pharma Conference

The 2nd Annual US-China Pharma Conference was held in May 9-10, 2012 in Philadelphia. This year, the main themes are “Outsourcing Drug Discovery in China” and “Beyond R&D: Partnership and Licensing Tactics”. The conference attracted over a hundred senior level delegates from pharmaceutical companies, CROs, venture capi...

Agenix sold its Hep B asset in China

Agenix sold its Hep B asset in China

 ASX Announcement 19 May 2014 Agenix sells its AGX 1009 China Asset to  Cinkate Pharmaceuticals for USD$2M Melbourne, Australia, 19 May 2014: Agenix Limited (ASX: AGX) advises that it has reached a binding Definitive Agreement for the sale of its AGX-1009 China project to Cinkate Pharmaceutical Intermediates Co Ltd (Cinkate), for USD $...

BFC Advised Ironwood for its China Deal

BFC Advised Ironwood for its China Deal

AstraZeneca and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) has signed agreemenet to co-develop and co-commercialize Ironwood's linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, 2012.  BFC Group acted as the BD advisor to Ironwood for its Chi...

BFC Group advised ICON plc for its MA in China

BFC Group advised ICON plc for its MA in China

ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, acquired BeijingWits Medical Consulting Ltd., a leading CRO in China.  BFC acted as Icon's advisor for the acqusition of Beijing Wits.   For detailed, please...

BFC Group co-organized China Forum III

BFC Group co-organized China Forum III

  China Forum III: Executing Joint Ventures in China: Structuring the Optimal Relationship    China Forum’s I and II educated attendees on the issues for emerging healthcare companies to approach relationships in China. Forum III will provide a tactical approach innovative joint venture structures that provi...

BFC led China Forum II discussion

BFC led China Forum II discussion

At the first China Forum, over 100 leading Chinese and US entrepreneurs, executives and investors discussed the growing opportunity in the rapidly expanding Chinese healthcare sector. Per capital healthcare spending in Hong Kong is eleven times that of China. In Japan it is twenty-two times. As China advances as an ec...

BFC co-organized China Forum IV again

BFC co-organized China Forum IV again

This is the fourth year in a row that BFC Group has particiated the China Forum IV during the JP Morgan Healthcare Conference. The director of BFC Group will act as moderator to discuss about the M&A and financing landscape in China and US.   Please see the program details in the following link.  http://www.onemedconferences.com/#!ag...

FREE NEWSLETTER
Email address: